We use a small number of cookies to give you the best experience of our website. If you continue to view the Positive Action site we'll assume that you are happy to receive these cookies. Find out exactly what cookies we use and how to turn them off.

Continue

HIV in the News

This page contains the most recent HIV related news from NAM aidsmap. You can read the full story by clicking on the headlines.

Second case of unintended HIV transmission during HIV cure study prompts questions about PrEP provision

A second case of HIV transmission from someone interrupting their HIV therapy as part of a cure study has been published. The report, by Dr Ainoa Ugarte, Dr Lorna Leal and colleagues from Barcelona University Hospital (Ugarte reference below) has prompted discussion about whether the HIV-negative partners of people involved in studies that feature so-called analytical treatment interruptions (ATIs) should be offered PrEP as a matter of course. ... full story

Intermittent and lower-risk PrEP users may not be testing for HIV and STIs, German study finds

A survey of German PrEP users reported at the recent 17th European AIDS Conference (EACS 2019) found that one in nine of them had not had a single HIV, STI or renal function test during the time they were on PrEP. Of those who had taken an HIV test while on PrEP, 15.5% had taken a test less often than the recommended interval of three months, and 8.5% had had an STI check-up less often than the recommended once every six months. ... full story

PrEP users have less HIV anxiety

Several qualitative studies have already found that gay and bisexual men using the preventative medication PrEP have reported benefits in terms of reduced anxiety about HIV, but until now there has been scarcely any quantitative data to confirm this. Now, an Australian study shows a statistically significant reduction in HIV anxiety among men who were eligible for PrEP and who were using it. ... full story

One-third of people living with HIV in rural Tanzania report clinically relevant drug-drug interactions

A study from rural Tanzania, published online ahead of print in HIV Medicine, provides more evidence on the importance of appropriate management of clinically relevant drug-drug interactions for people living with HIV who are on antiretroviral therapy. As life expectancy of people living with HIV has increased due to improved access to antiretroviral therapy (ART), co-morbidities and co-medications are also on the rise. But appropriate management of clinically relevant drug-drug interactions is sub-optimal, especially in low-resource settings. ... full story

Serosorting between gay men may be in decline as ?PrEP sorting? rises, Canadian study finds

A Canadian study which compared the HIV status of gay men?s recent sexual partners with what would be expected if they chose partners regardless of status has found that HIV-negative men who used PrEP were nearly twice as likely to have HIV-positive partners as those who did not. It also found that men using PrEP were more likely to have sex with other PrEP users than with men not using PrEP. Conversely, non-users were more likely to have sex with non-users. ... full story

Rates of pneumonia and pneumococcal disease remain high among people with HIV

The incidence of invasive pneumococcal disease and community-acquired pneumonia remains high among people living with HIV, investigators from the Netherlands report in Clinical Infectious Diseases. Rates of these serious lung infections were highest among people not taking anti-HIV drugs and with CD4 cell count below 500. ... full story

Hepatitis C incidence is low among Canadian men on PrEP

New cases of hepatitis C virus (HCV) infection among Canadian gay and bisexual men taking pre-exposure prophylaxis (PrEP) were uncommon compared with rates previously reported in Europe, according to research presented this week at the AASLD Liver Meeting in Boston. ... full story

How do we deal with apparent cases of PrEP failure?

The 17th European AIDS Conference (EACS 2019) in Basel, Switzerland, last week, heard about another case of a PrEP user who caught HIV despite being apparently adherent to PrEP. ... full story

96-week results of DISCOVER PrEP trial presented at European AIDS Conference

The 96-week results of the DISCOVER trial, which compared the efficacy and safety of two different formulations of the antiretroviral drug tenofovir when used as daily PrEP by gay and bisexual men, were announced at the 17th European AIDS Conference (EACS 2019) in Basel last week. ... full story

Options for two-drug simplification expand

Further evidence on the efficacy of two-drug antiretroviral regimens as simplification options for people with suppressed viral load on three-drug regimens was presented last week at the 17th European AIDS Conference in Basel, Switzerland. ... full story

Tenofovir (TDF) does not increase risk of kidney disease in people at low risk

Antiretroviral treatment containing the older formulation of tenofovir (tenofovir disoproxil fumarate; TDF) did not increase the risk of chronic kidney disease in previously untreated people with HIV at low risk for kidney disease, a large American cohort study reported last week at the 17th European AIDS Conference in Basel, Switzerland. ... full story

HIV-positive gay men in England report highest chemsex rates in four-country survey

A study presented at the recent 17th European AIDS Conference (EACS 2019), comparing reported drug use among HIV-positive men attending clinics in England, Spain, Greece and Italy, has found higher rates of drug use in England than in other countries and considerably higher usage of the drugs used in chemsex (sexualised drug use) ? methamphetamine, GHB/GBL, mephedrone and ketamine. ... full story

Coalition of liver associations call for simplifying hepatitis C care

Leaders of liver disease associations from Europe, the United States, Latin America and Asia issued a global call to action at The Liver Meeting this week in Boston, aiming to advance toward the goal of eliminating hepatitis C as a public health threat. Approximately 71 million people worldwide have chronic hepatitis C virus (HCV), and around 1.75 million more acquire the virus annually, according to the American Association for the Study of Liver Diseases (AASLD), which sponsors the conference. ... full story

Dolutegravir and raltegravir cause changes to fat cells

The integrase inhibitors dolutegravir (Tivicay, also in Triumeq and Dovato) and raltegravir (Isentress) cause changes in the structure of fat cells that may promote obesity, and can cause insulin resistance, studies of cells sampled from people living with HIV and monkeys exposed to the drugs have found. The findings were presented last week at the 17th European AIDS Conference (EACS 2019) in Basel, Switzerland. ... full story

Weight gain after switching to integrase inhibitor treatment is small in Dutch and Swiss cohorts

People with suppressed viral load who switched to an integrase inhibitor-based regimen experienced only small gains in weight and do not appear to gain more weight than HIV-negative people or people who continued taking other regimens, two large cohort studies presented at the 17th European AIDS Conference (EACS 2019) reported. ... full story

French study finds one in six stops PrEP within 12 months, one in three after 30 months

PREVENIR, the French open-label study looking at PrEP use in gay and bisexual men in the Paris region, has found that 16% of study participants either told clinicians they were stopping PrEP or disappeared from the study within a year, and that 32% had discontinued PrEP after 30 months. Younger men (aged 25 and under), people who had never taken PrEP before and men with poorer education were all more likely to discontinue PrEP than other men in the study.  ... full story

New European HIV guidelines cater for multiple needs

The tenth edition of the European AIDS Clinical Society Guidelines was launched at the society's 17th European AIDS Conference (EACS 2019), in Basel, Switzerland last Thursday. Its expansion in size ? from 109 pages in the ninth print edition first published two years ago to 283 pages today, plus numerous online-only supplementary tables ? is evidence of the complexity of needs it seeks to address. ... full story

Anal cancer: Australian study of precancerous tissues in gay men shows little increased risk in positive men, almost no cancer cases

An Australian study of gay men recruited in community settings in Sydney, Australia has found a very high prevalence of HSIL (high-grade squamous intraepithelial lesions ? precancerous changes in the cells of the anal lining that may indicate a risk of developing cancer). Yet in three years of follow-up, only one man out of 617 progressed to anal cancer, the 17th European AIDS Conference (EACS 2019) in Basel, Switzerland heard. ... full story

ADVANCE study shows high frequency of major weight gain in women receiving dolutegravir with TAF

Metabolic syndrome ? including obesity ? developed significantly more frequently in people who received dolutegravir, tenofovir alafenamide (TAF) and emtricitabine compared to other regimens in the South African ADVANCE study, Dr Michelle Moorhouse reported on Thursday at the 17th European AIDS Conference in Basel, Switzerland. ... full story

Weight gain on HIV treatment: drug combinations, not single drugs, need to be focus of quest for cause

Weight gain after starting antiretroviral treatment probably has multiple causes but appears strongly linked to specific drugs, and to combinations of drugs, Dr Andrew Hill of the University of Liverpool told the 17th European AIDS Conference in Basel, Switzerland, on Thursday. ... full story


You can read older stories on the NAM aidsmap news page.